Answers are grounded in this paper and cite their sources.
Retrospective analysis compares standard and modified gemcitabine with nab-paclitaxel effectiveness in Latin American metastatic pancreatic adenocarcinoma patients, indicating similar outcomes.
Gemcitabine plus nab-paclitaxel (GnP) is one of the standard chemotherapy regimens in the management of metastatic pancreatic adenocarcinoma (MPA). Little information is available on the real-world effectiveness and safety of GnP in Latin Americans and the role of modified GnP in this population. This is a retrospective, unicentric study. We included chemotherapy-naïve patients with MPA diagnosed from 2015 to 2022 who started first-line with GnP. We compared the clinical characteristics, treatment outcomes, and safety profiles of patients treated with standard or modified GnP. The study population consisted of 52 patients. Those treated with standard GnP had less comorbidity as measured by Charlson Comorbidity Index (median: 0 vs. 1; p = 0.023). Overall response and disease control rates were 28.6 and 57.1% in the standard GnP arm and 11.8 and 58.8% in the modified GnP, respectively. There were no differences in median overall survival (10.1 vs. 12.1 months; p = 0.739) or median progression-free survival (6.4 vs. 5.7 months; p = 0.306). Patients treated with modified GnP had numerically lower rates of grades 3 or higher neutropenia (28.6 vs. 5.9%; p = 0.078) and thrombocytopenia (20.0 vs. 0.0%; p = 0.081). The activity and safety profiles of GnP in this Latin American cohort are comparable to those seen in other populations. The modified regimen is associated with similar clinical effectiveness and lower chances of hematological toxicity, when compared with standard GnP.
No takes yet. Share an insight, caveat, or question.
Jesus et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: